Trial Profile
A Phase III Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Sep 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2016).
- 15 Feb 2016 New trial record